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Liddle syndrome is a rare form of autosomal dominant hyper-
tension with early penetrance and impressive cardiovascular se-
quelae. The basic features of this syndrome were described in a
large kindred from Alabama by Grant Liddle and co-workers in
1963 [1]. In addition to severe hypertension, many of the patients
had overt hypokalemia. Despite having the clinical presentation
typical of primary aldosteronism, the actual rates of aldosterone
excretion were markedly suppressed, accounting for the descrip-
tive term “pseudoaldosteronism.” Liddle’s original publication is a
classic description of clinical investigation; spironolactone, a
mineralocorticoid antagonist did not have any discernible effect,
while triamterene normalized the blood pressure, reversed the
renal potassium wasting and corrected the hypokalemia as long as
the subjects restricted their dietary salt intake. Liddle correctly
interpreted these findings as indicating an intrinsic renal defect in
the regulation of salt absorption rather than the effects on the
distal tubule of some unidentified mineralocorticoid other than
aldosterone [1]. This interpretation has been strengthened by the
finding that renal transplantation also corrects most of the
abnormalities in Liddle syndrome [2, 3].
Liddle syndrome is an extreme example of low renin, volume-
expanded hypertension. Tremendous progress has been made in
understanding unusual forms of low renin hypertension at the
level of discrete genetic mutations [4]. We now have much better
knowledge of the underlying pathophysiology of glucocorticoid-
remediable aldosteronism [5], Liddle syndrome (pseudoaldoste-
ronism) [6], and the apparent mineralocorticoid excess syndrome
[7]. The functional effects of the specific mutations described in
each of these syndromes have been confirmed with expression
studies in various systems. In general, inappropriate renal Na1
retention with subsequent volume expansion, low plasma renin
activity and hypertension are the consequences of unusual or
inappropriate mineralocorticoid excess, or in the case of
“pseudoaldosteronism,” apparent mineralocorticoid excess that
results from constitutive activation of the amiloride-sensitive
epithelial Na1 channel (ENaC) in the terminal nephron seg-
ments.
The original pedigree described by Liddle, Bledsoe and Cop-
page [1] was Caucasian. Other pedigrees, including Japanese
[8–10], Hispanic [11], and African-American [12] families have
been described. These cases may not have presented with severe
hypertension at an early age, but in retrospect, after extensive
(and expensive) diagnostic work-ups for secondary hypertension,
these patients were found to have pseudoaldosteronism with
long-standing hypokalemia and hypertension.
The original index case (“GS”) developed renal failure in 1989,
and underwent successful renal transplation (cadaver donor) at
the University of Alabama at Birmingham. The subsequent
improvement in her condition [2] confirmed Liddle et al’s theory
that pseudoaldosteronism is “a disorder in which the renal tubules
transport ions with such abnormal facility that the end result
simulates that of a mineralocorticoid excess” [1]. A previous
report from Paris described a pair of sisters with Liddle syndrome
who developed renal insufficiency, presumably from hypertension;
the older sister underwent renal transplantation at the age of 23,
and her hypokalemia and severe hypertension were corrected [3].
These cases are notable because the incidence of severe renal
insufficiency in Liddle syndrome is distinctly unusual [2]. Cardio-
vascular and cerebrovascular complications of hypertension are
much more common findings, and the usual cause of death in
undiagnosed or untreated patients.
GENETIC LINKAGE STUDIES AND MUTATION ANALYSES
The size of the original pedigree and careful clinical assessment
of the members at risk [2] demonstrated that Liddle syndrome is
an autosomal dominant disorder, and also provided the material
required for genetic linkage analysis that permitted the identifi-
cation the causal mutation in the beta subunit of the amiloride-
sensitive Na1 channel [6]. The subunits of the epithelial sodium
channel (ENaC) complex have been defined by expression cloning
in the Xenopus oocyte expression system, were recognized as
important candidate genes for the cause of Liddle syndrome at the
time of the initial description of the structure and function of the
channel subunits by Canessa and Rossier [13, 14]. The ENaC
complex is composed of three homologous subunits, each of which
has two membrane spanning regions and a large extracellular
domain with glycosylation sites and cysteine-rich regions. The N9-
and C9-terminal domains of each subunit are located in the
cytoplasm, but comprise relatively minor amounts of the protein
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chains. The actual stoichiometry of the ENaC complex has not yet
been determined. Each ENaC complex is assumed to contain at
least one of each of the three currently defined subunits, but the
actual ratio of subunits needs to be defined. These issues are
thoroughly reviewed in the recent Homer Smith Lecture by
Bernard Rossier [15].
While the genetic linkage results clearly implicated the beta
subunit as the locus of interest, the most striking finding was the
demonstration of premature stop codons and frame-shifts in four
independent pedigrees [6]. The identification of these mutations
in the coding domain of the beta subunit was guided by analogous
mutations previously described in homologous gene products that
are expressed in Caenorhabditis elegans, which appear to be
involved in mechanotransduction [16–18]. The mutations de-
scribed in C. elegans were in the second transmembrane region,
and the original mutations described in Liddle syndrome was
immediately adjacent in the cytosolic tail of the beta subunit [6].
Description of these specific mutations has established Liddle
syndrome as a cardinal example of familial hypertension in which
a physiologically plausible candidate gene has been functionally
linked to the underlying pathophysiology of the disease.
The deduced amino acid sequence of the beta subunit, and the
location of its currently described mutations [6] are presented in
Figure 1. It is curious that all of the defined mutations in
pedigrees with Liddle syndrome fall within a very narrow range of
30 amino acids of the cytosolic tail of the beta subunit. An
analogous mutation to that in the original pedigree (bR564X) has
been described in the gamma subunit [19]. Although suggested by
expression studies in the oocyte system [20], causal truncating
mutations in the cytosolic tail of the alpha subunit have not yet
been described in any human subjects.
Missense mutations in the proline-tyrosine motif (PPPXY) of
the beta subunit have also been described which constitutively
activate ENaC activity [10, 21]. These missense mutations are also
Fig. 1. Cytoplasmic domains of the mutated beta subunits in Liddle syndrome. The wild-type sequence is shown at the top; each of the subsequent
listings represent distinct pedigrees. The outlined PPPNY sequence in the wild-type represents a Nedd4 binding domain [22], which is deleted in each
of the affected pedigrees described in the original publication [6]. (A) Truncating mutations. Pedigrees K100 (the original pedigree described by Liddle)
and K175 have premature terminations of the beta subunit (bR564X, and bF589IX) due to mutations which introduce stop codons into the translated
sequence. Pedigrees K176 and K101 have frame-shifts with abnormal protein sequences followed by new stop codons. (B) Missense mutations. Point
mutations are illustrated (underlined) which change the critical PPPNY domain of the beta subunit [10, 21, 46].
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illustrated in Figure 1, and confirm the importance of this region
previously suggested by in vitro expression studies [20] as well as
studies of the apparent interaction of these regions with alpha
spectrin (for the alpha subunit) and the Nedd4 protein for all
three subunits [22, 23]. The latter protein appears to play a role in
the assembly, insertion and/or or retrieval of the ENaC complex
membrane in the plasma membrane.
EXPRESSION STUDIES
Oocyte expression studies have defined the alpha subunit as the
most critical entity in the channel complex which by itself can
express amiloride-sensitive sodium channel activity [13, 24–26].
Kleyman and co-workers have recently identified an 8 amino acid
stretch in the extracellular loop of the alpha subunit that appears
to be intimately involved in the amiloride-binding site [27]. Schild
et al [28] have recently used site directed mutagenesis to define a
short region (pre-M2 segment) that immediately precedes the
second membrane spanning region of all of the defined members
of the ENaC gene family that strikingly affects cation permeation
and amiloride sensitivity. These pre-M2 segments are hypothe-
sized to be involved in the transmembrane ion permeation
pathway [28]. The beta and gamma subunits appear to stabilize
the expression of alpha subunit [13, 24, 25], and also appear to
participate in the ion permeation pathway and to convey amilo-
ride sensitivity [28]. It would not be surprising if additional
mutations were discovered in the cytosolic and pre-M2 domains of
the beta and gamma subunits, judging from their role in the
expression of ENaC activity. Because of its critical role, truncating
mutations in the alpha subunit have been associated with com-
plete non-functioning of the channel complex (pseudohypoaldo-
steronism, type I [29]). Resistance to inhibition by amiloride and
triamterene could also result from mutations in the extracellular
loops of the subunits, but these have yet to be described in human
subjects.
CELLULAR PHENOTYPE
We have extended earlier studies [30] of red cell Na1 fluxes in
Liddle syndrome, and have described, in affected members of the
original pedigree, constitutive activation of the amiloride-sensitive
Na1 channel in B lymphocytes [31]. While it is not yet established
that the same factors regulate the amiloride-sensitive sodium
channel in the B cell as in the principal of the collecting tubule, it
has been demonstrated with whole cell patch clamp studies that
the amiloride-sensitive sodium channels in both systems are
pharmacologically and functionally quite similar [32, 33]. At
present, specific mutations in the beta subunit have been identi-
fied in a number distinct kindreds (Fig. 1). While continued
surveys of affected kindreds such as described by Gadallah, Abreo
and Work [12] may ultimately define the entire set of relevant
mutations in pseudoaldosteronism, the functional screening of the
relevant cellular phenotype by electrophysiologic or fluorescence-
based techniques may also be an important approach to define the
extent of constitutive activation of epithelial sodium channels in
low-renin hypertension.
The previous studies of cellular physiology clearly demonstrate
activated sodium channel activity in non-epithelial tissues [30, 31].
It seems certain that expression of ENaC-like activity is not,
therefore, limited to classical epithelial tissues. We have recently
demonstrated that the beta ENaC subunit mRNA can be dem-
onstrated in lymphocytes by reverse transcriptase/polymerase
chain reaction, and that lymphocytes from the original Liddle’s
pedigree demonstrate an equal mixture of wild-type (WT) and
mutated (bR564X) messages, consistent with autosomal domi-
nant inheritance [34]. It has not yet been possible to define the
sequence of the putative alpha subunit expressed in lymphocytes,
presumably due to extremely low message abundance. Recently,
several other variants of the alpha subunit have been described
[35–38]. Thus, there may be a number of members of the ENaC
gene family, and their expression is not limited to epithelial
systems.
MOLECULAR PATHOPHYSIOLOGY
The identification of specific Nedd4 and alpha spectrin binding
domains in the cytosolic region of the ENaC subunits [22, 23], and
the analysis of these domains by site directed mutagenesis [20]
suggest that interactions with cytoskeletal elements may control
the expression of ENaC complexes at the membrane surface. The
well described interactions of ENaC with actin and other cytoskel-
etal elements are notable in this regard [39]. Therefore, some sort
of membrane retrieval mechanism may be important in regulating
ENaC activity. It appears that this process is effected by interac-
tions of the PPPXY sequence in the cytosolic tails of the ENaC
subunits with the cytosolic retrieval mechanism [20, 22, 23]. It is
notable that all of the mutations described in Liddle syndrome
which are associated with constitutive activation of ENaC activity,
either truncate the beta or gamma subunits before the critical
PPPXY domain, or cause missense mutations within this domain
(Fig. 1).
None of the previous expression studies have definitively dis-
tinguished between constitutive activation due to increase open
probability of individual channels, or increased number of chan-
nels expressed at the membrane surface. Rossier and colleagues
[24] have recently examined this issue in the oocyte expression
system using ENaC constructs to which a defined epitope
(FLAG®, Kodak; DYKDDDDK) was added to the external loop
of each subunit. These additions did not affect channel activity,
but permitted immunoprecipitation and surface labeling. With
this approach, surface expression of the ENaC complex could be
quantitated by binding of iodianted monoclonal antibodies to the
FLAG epitope on the surface of intact oocytes.
There was nearly a fivefold difference in amiloride-sensitive
Na1 current when ENaC was expressed in oocytes with the
originally described beta subunit mutation, as was previously
described [40]. While there was a 1.9-fold increase in surface
binding of the ENaC complex when the bR564X construct was
compared to the wild-type (WT), there was a much larger increase
(.5-fold) when the slopes of the current/binding site regressions
were compared (Fig. 2). Therefore, the major effect of the
originally described truncating mutation was to increase the
conductance of the individual ENaC complex (such as the open
probability), rather than to increase the number of channels in the
plasma membrane. Thus, the membrane retrieval theory can
account for some of the increased constitutive activation observed
with the truncating beta mutation, but a far greater effect is
observed when the current per binding site is considered.
Additional insights into the regulation of amiloride-sensitive
sodium channel activity has been obtained from complexes recon-
stituted in lipid bilayers [41], and from the B lymphocyte system
[42]. Sodium channel activity can be described with a dual
regulation model, including reciprocating pathways for protein
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kinase A (PKA) and protein kinase C (PKC) in B cells and the
oocyte expression system [33, 43]. Constitutive activation of
sodium channel activity with the bR564X mutation may reflect
enhanced sensitivity of the channel complex and its associated
proteins [39] to the activating effects mediated by PKA. Inhibition
of PKA with a competitive inhibitor of cAMP binding to the
regulator site [44] reduced the constitutive activated sodium
current in lymphocytes from affected patients to basal levels of
activity [42]. Of interest, addition of the missing terminal ten
amino acids of the beta subunit also restored the current to basal
levels in both the B cell [42] and reconstituted channel system.
[41]. This specific peptide (IESDSEGDAI) has a net negative
charge and is deleted by the truncating mutations shown in Figure
1A. It was hypothesized that this peptide interacts with some
target for PKA-mediated phosphorylation on the channel com-
plex (subunits or associate cytoskeletal elements), and affects the
activity of the complex by altering its phosphorylation state [41,
45]. This explanation may not be relevant for the missense
mutations shown in Figure 1B since the terminal peptide has not
been conserved. In addition, truncation of the terminal ten amino
acids of the beta subunit does not activate the rat ENaC system
expressed in oocytes [20], while the same truncation does appear
to be activating when human ENaC subunits are expressed in
oocytes [26]. While the effects of the terminal peptide are
somewhat controversial, it does appear certain that originally
described mutation (bR564X) effects constitutive activation of
the channel complex per se [24], and that this activation appears to
represent an enhanced sensitivity to the activating effects (via
PKA) of normal endogenous cAMP levels [33, 42]. Further
studies are needed to define the phosphorylated components of
the channel complex and/or its associated cytoskeletal elements,
and the mechanism by which the PKA-mediated phosphorylation
causes constitutive activation of amiloride-sensitive sodium chan-
nel activity. A T594 M mutation has been described in the beta
subunit of some African-Americans which appears to increase the
cAMP-sensitivity on sodium channel activity in B lymphocytes
[46]. There was not any obvious relationship of this polymorphism
to hypertension or plasma renin levels in these individuals, while
there was an increased plasma aldosterone level in these subjects.
Nevertheless, this study raises the possibility that polymorphisms
that exist in the general population may affect the sensitivity of
ENaC to regulator influences [46, 47].
CLINICAL DIAGNOSIS OF LOW RENIN HYPERTENSION
At present, Liddle syndrome joins the ranks with glucocorti-
coid-remediable aldosteronism (GRA) as Mendelian forms of
severe hypertension marked by early penetrance and substantial
target organ damage. Glucocorticoid-remediable aldosteronism is
another rare, autosomal dominant form of familial hypertension
for which the causal genetic defect has recently been identified by
Lifton and co-workers [5, 48]. This syndrome is caused by a
chimeric gene duplication arising from unequal crossing-over,
such that the regulatory sequences of steroid 11 b-hydroxylase
control the expression of the coding sequences of aldosterone
synthase. The chimeric gene product is expressed, under the
control of ACTH, in both the zona glomerulosa and zona
fasciculata [49]. Since the chimeric gene product is expresses
throughout the adrenal cortex, the production of 18-hydroxy
cortisol and aldosterone metabolites is increased and can be
suppressed by dexamethasone suppression of ACTH secretion.
A number of cross-over points have been described in a number
of different pedigrees, but the cross-over point in a given pedigree
is conserved and contained within the intron 2 to intron 4 stretch
of the parental genes. The possibility of a susceptibility allele for
GRA of Irish origin is suspected [50], and the syndrome has not
yet been described in African-Americans. While the severity of
hypertension, early penetrance, and autosomal dominant inheri-
tance [50] are similar to Liddle syndrome [2], these disorders can
be readily distinguished by the pattern of urinary steroid excretion
Table 1. Urinary steroid profiles in mendelian forms of
low renin hypertension
Liddle syndrome GRA AME
Aldosterone ss 1 2
TH-Aldo ss 1 2
18-OH-TH-Aldo ss 1 2
18-OH F 2 aa 2
TH-F nl nl a
TH-E nl nl s
TH-F/TH-E nl nl aa
Urinary steroid profiles are performed with gas chromatography/mass
spectroscopy [58] by the Quest Diagnostic Lab (San Juan Capistrano, CA,
USA). Abbreviations are: GRA, glucocorticoid remedial aldosteronism;
AME, apparent mineralocorticoid excess; nl, normal; 2, not usually
detected; TH-aldo, tetrahydro-aldosterone; 18-OH-TH-Aldo, 18-OH tet-
rahydro-aldosterone; 18-OH F, 18-OH cortisol; TH-F, tetrahydro-cortisol;
TH-E, tetrahydro-cortisone; TH-F/TH-E, ratio of TH-F to TH-E.
Fig. 2. Effects of a beta subunit truncating mutation (bR564X) on the
amiloride-sensitive sodium current, surface binding, and current per
binding site for wild type (WT) and the mutation described in the original
Liddle pedigree (bR564X). Amiloride-sensitive current (mM) per oocyte
was measured with a two electrode technique at 2100 mV. Binding sites
(fmol/oocyte) were determined in individual oocytes with an 125I-labeled
monoclonal antibody to the FLAG epitope. The slope (mA/fmol), which is
a measure of amiloride-sensitive current normalized for surface expres-
sion of ENaC was obtained from the regression of current versus binding
sites for at least 15 oocytes injected with the WT or bR564X cRNA along
with alpha and gamma cRNA. Each of the ENaC subunits incorporated
the FLAG epitope into the extracellular loop. Modified from reference
[24]. Symbols are: (u) INa mA; (f) slope mA/fmol; (M) binding fmol/
oocyte.
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with increased 18-OH-cortisol and 18-oxocortisol in GRA, and
suppressed aldosterone and aldosterone metabolite excretion in
Liddle syndrome.
The apparent mineralocorticoid excess syndrome (AME) is
another rare Mendelian form of hypertension that is most often
inherited as an autosomal recessive disorder [7, 51]. Mutations in
this disorder disrupt the 11-b-OH steroid dehydrogenase, type II
gene which uni-directionally metabolizes cortisol to cortisone, and
prevents cortisol from expressing mineralocorticoid effects in
target tissues. With these mutations, or with exogenous inhibitors
of this enzyme (such as licorice [52]) a fairly typical picture of
mineralocorticoid excess is seen, including hypertension and
potassium wasting with metabolic alkalosis. Once again, the
definitive clinical diagnosis is made by analysis of the urinary
steroid profiles since there is increased excretion of reduced
cortisol metabolites compared to reduced cortisone metabolites.
In addition, the mineralocorticoid excess and resulting volume
expansion suppresses plasma renin activity and aldosterone secre-
tion.
The incidence of Liddle syndrome [12] and GRA [50] may be
greater that originally appreciated, and an appropriate level of
clinical suspicion must be maintained. Analysis of urinary steroid
profiles is worthwhile, and represents a cost-effective approach to
the work-up of secondary hypertension. While low-renin hyper-
tension in the adult is relatively common, and the great majority
of these individuals will not have one of the currently described
Mendelian causes of hypertension [4], the finding of low renin
hypertension in a child, especially with a provocative family
history warrants a consideration of the monogenic causes of
hypertension [53]. Overt hypertension may be detected in affected
patients with either Liddle syndrome and GRA without overt
hypokalemia or renal potassium wasting [2, 50]. Therefore, the
clinical adage that unexplained hypokalemia in a hypertensive
patient is an indication for working-up secondary causes of
hypertension is not all inclusive. Patients will be missed who are
not overtly hypokalemic but do have a secondary cause of their
hypertension. The true prevalence of Liddle syndrome and GRA
in low-renin hypertension remains to be defined, but only account
for a minority of such cases. Clinicians can sharpen their diagnos-
tic skills by recognizing the importance of a strong family history
of severe hypertension with target organ damage, and gaining a
working familiarity with the analysis of urinary steroid excretion
patterns as they pertain to Liddle syndrome, GRA and the
Apparent Mineralocorticoid Excess syndrome (Table 1). In the
more common forms of low renin hypertension for which a
genetic cause is not yet defined, the measured aldosterone levels
and excretion are relatively normal despite suppression of plasma
renin activity, suggesting a state of relative mineralocorticoid
excess [54]. Bilateral adrenal hyperplasia or adrenal adenomas
would present with suppression of plasma renin activity, but the
plasma levels and urinary excretion of aldosterone and its metab-
olites would be distinctly elevated. In fact, plasma aldosterone
levels may be normal even though the 24-hour urinary excretion
of aldosterone metabolites is distinctly elevated in some patients
with adrenal adenomas (personal observation).
TREATMENT OF LIDDLE SYNDROME
While the monogenic forms of human hypertension are quite
rare compared to the usual form of low renin hypertension seen in
African Americans [47, 55], several relevant therapeutic insights
have emerged from the studies of the Mendelian forms of human
hypertension. Treatment of Liddle syndrome has increased our
appreciation of the use of K1-sparing diuretics. While spirono-
lactone is not useful in Liddle syndrome [1], it could be considered
in low renin hypertension since the aldosterone excretion rates are
“normal” despite suppression of plasma renin activity [47, 54]. In
Liddle syndrome, there appear to be some pedigrees that are
more responsive to amiloride and others in whom triamterene is
more effective [45]. In every instance, the utility of amiloride and
triamterene are enhanced by dietary salt restriction. This clinical
observation is understandable in light of the known competition
between these agents and Na1 at the level of the ENaC conduct-
ing pore [56].
Low cost preparations of amiloride and triamterene are avail-
able that contain either agent in combination with a thiazide
diuretic, but the amount of thiazide is excessive compared to the
amount of K1 sparing diuretic. While these combinations are
useful in treating the underlying Na1 retention, the thiazide
component may worsen renal K1 wasting in susceptible patients,
especially if dietary salt intake continues to be excessive. Rather
than fixed dose combinations, it may be necessary to specifically
increasing the dosage of triamterene or amiloride as well as
reducing dietary salt intake in patients receiving thiazides or
furosemide for their effective volume expansion.
While amiloride or triamterene alone may be adequate to
control the hypertension in patients with Liddle syndrome, older
patients may not have adequate blood pressure control despite
resolution of their K1 wasting with these agents. Continued use of
the K1 sparing agents is worthwhile, but the hypertension must be
treated aggressively with vasodilators and/or beta blockers to
minimize cardiovascular and cerebrovascular morbidity.
Since the causal mutations are conserved within pedigrees with
Liddle syndrome, it is possible to use genetic screening at a young
age of children at risk. While pre-natal diagnosis does not seem
worthwhile, and any such genetic screening raises serious legal
and ethical issues [53], genetic counseling is useful in this auto-
somal dominant condition if one of the parents is known to be
affected. The utility of this approach is to enhance and target
surveillance of at-risk subjects at an early age since each child of
an affected parent has a 50% chance of inheriting the mutated
allele from the affected parent. It should be kept in mind that
there were a few subjects described in the original pedigree [2]
who were not overtly hypertensive or hypokalemic despite being
subsequently identified as carrying the causal mutation [6]. Con-
tinued surveillance of these subjects is necessary.
Can any of these principles be applied to treatment of the much
more common form of low renin hypertension in which the
genetic cause(s) have yet to be identified? The utility of dietary
salt restriction, and a more aggressive use of the K1 sparing
diuretics would seem worthwhile. It is probably important to
coordinate the administration of the K1 sparing diuretics with the
pattern of dietary salt intake. Bedtime dosing with amiloride or
triamterene is not recommended when the bulk of the dietary salt
intake and excretion occurs during waking hours. It is possible
that there are subsets of patients who may respond to amiloride
but not to triamterene, and others that would best be treated with
triamterene rather than amiloride. Therefore, both agents should
be tried in an individual patient before abandoning the use of K1
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sparing diuretics. These agents would seem preferable to spirono-
lactone because of its anti-androgen side effects (gynecomastia,
benign prostatic hypertrophy, etc.), but spironolactone is certainly
recognized as a component of the therapy of primary aldosteron-
ism [57]. If renal function is normal, and dietary K1 intake is not
excessive, there should not an be untoward incidence of hyperka-
lemia in patients with low renin hypertension who are treated with
K1 sparing diuretics, but monitoring of the serum electrolytes is
worthwhile.
Finally, it is important to remember that there are well de-
scribed examples of patients who are hypertensive and have
Liddle syndrome [2] or GRA [50], but who are not overtly
hypokalemic. This observation greatly weakens the use of hypo-
kalemia as screening test for secondary and/or endocrinologic
causes of human hypertension. Despite the lack of overt potas-
sium wasting, an argument can be made for the use of K1-sparing
diuretics in these patients, and by inference in patients with low
renin hypertension without a defined genetic cause if an underly-
ing cause of the enhanced renal Na1 absorption is dysregulation of
ENaC activity, especially when dietary salt intake is increased [47].
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